FACS analysis of human peripheral blood lymphocytes using GTX01455-11 CD19 antibody [HIB19] (PerCP-Cy5.5). Solid lone : primary antibody Dashed line : isotype control antibody amount : 0.125 microg (5 microl)
FACS analysis of human peripheral blood lymphocytes using GTX01455-11 CD19 antibody [HIB19] (PerCP-Cy5.5). Solid lone : primary antibody Dashed line : isotype control antibody amount : 0.125 microg (5 microl)
CD19 antibody [HIB19] (PerCP-Cy5.5)
GTX01455-11
Overview
- SupplierGeneTex
- Product NameCD19 antibody [HIB19] (PerCP-Cy5.5)
- Delivery Days Customer9
- Application Supplier NoteFACS: 0.125 microg (5 microl) for 105-108 cells in 100 microl sample per test. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsFlow Cytometry
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDHIB19
- Concentration0.025 mg/ml
- ConjugateDouble Conjugated
- FormulationLiquid
- Gene ID930
- Target nameCD19
- Target descriptionCD19 molecule
- Target synonymsB4; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CVID3; differentiation antigen CD19; T-cell surface antigen Leu-12
- HostMouse
- IsotypeIgG1
- Protein IDP15391
- Protein NameB-lymphocyte antigen CD19
- Scientific DescriptionLymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. [provided by RefSeq, Jul 2008]
- ReactivityHuman
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans. Richards KA et al., 2020, NPJ VaccinesRead more
- Natural killer cell phenotype is altered in HIV-exposed seronegative women. Zhao NQ et al., 2020, PLoS OneRead more
- Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency. Stoszko M et al., 2020 Aug, Sci AdvRead more
- Activation of Toll-Like Receptors Differentially Modulates Inflammation in the Human Reproductive Tract: Preliminary Findings. Benjelloun F et al., 2020, Front ImmunolRead more
- CD70 Deficiency Associated With Chronic Epstein-Barr Virus Infection, Recurrent Airway Infections and Severe Gingivitis in a 24-Year-Old Woman. Krueger R et al., 2020, Front ImmunolRead more
- IL-34 Actions on FOXP3(+) Tregs and CD14(+) Monocytes Control Human Graft Rejection. Bezie S et al., 2020, Front ImmunolRead more
- Interferon-alpha alters host glycosylation machinery during treated HIV infection. Giron LB et al., 2020 Sep, EBioMedicineRead more
- Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. Salzer B et al., 2020 Aug 20, Nat CommunRead more
- A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model. Kreye J et al., 2020 Aug 16, bioRxivRead more
- Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. Pierini S et al., 2020 Aug 20, JCI InsightRead more